Glaukos and Attillaps Holdings have entered into a licensing agreement that grants Glaukos a global exclusive license to Attillaps’ library of proprietary investigational compounds targeting Demodex mites, according to a press release.
The agreement grants Glaukos exclusive right to develop, manufacture and commercialize products using acetylcholinesterase inhibitors to treat Demodex-related ophthalmic diseases.
“This licensing agreement adds a promising therapeutic class that expands the focus of our emerging corneal health franchise into new and globally underserved disease